Cambridge Nutritional Sciences Balance Sheet Health
Financial Health criteria checks 6/6
Cambridge Nutritional Sciences has a total shareholder equity of £9.5M and total debt of £0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are £13.5M and £4.0M respectively.
Key information
0%
Debt to equity ratio
UK£0
Debt
| Interest coverage ratio | n/a |
| Cash | UK£4.52m |
| Equity | UK£9.54m |
| Total liabilities | UK£3.96m |
| Total assets | UK£13.50m |
Recent financial health updates
We Think Omega Diagnostics Group (LON:ODX) Needs To Drive Business Growth Carefully
Nov 06
Companies Like Omega Diagnostics Group (LON:ODX) Are In A Position To Invest In Growth
Jun 14We're Hopeful That Omega Diagnostics Group (LON:ODX) Will Use Its Cash Wisely
Dec 09
Recent updates
Investors Don't See Light At End Of Cambridge Nutritional Sciences plc's (LON:CNSL) Tunnel
Nov 19The Market Doesn't Like What It Sees From Cambridge Nutritional Sciences plc's (LON:CNSL) Revenues Yet
Jul 27Cambridge Nutritional Sciences plc's (LON:CNSL) Shares Lagging The Industry But So Is The Business
Mar 14We Think Omega Diagnostics Group (LON:ODX) Needs To Drive Business Growth Carefully
Nov 06This Is Why Omega Diagnostics Group PLC's (LON:ODX) CEO Compensation Looks Appropriate
Sep 09Companies Like Omega Diagnostics Group (LON:ODX) Are In A Position To Invest In Growth
Jun 14How Does Omega Diagnostics Group's (LON:ODX) CEO Salary Compare to Peers?
Mar 01Announcing: Omega Diagnostics Group (LON:ODX) Stock Soared An Exciting 301% In The Last Year
Feb 01What You Need To Know About Omega Diagnostics Group PLC's (LON:ODX) Investor Composition
Jan 04We're Hopeful That Omega Diagnostics Group (LON:ODX) Will Use Its Cash Wisely
Dec 09Financial Position Analysis
Short Term Liabilities: CNSL's short term assets (£7.5M) exceed its short term liabilities (£1.5M).
Long Term Liabilities: CNSL's short term assets (£7.5M) exceed its long term liabilities (£2.5M).
Debt to Equity History and Analysis
Debt Level: CNSL is debt free.
Reducing Debt: CNSL has no debt compared to 5 years ago when its debt to equity ratio was 7.6%.
Debt Coverage: CNSL has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CNSL has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 21:12 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cambridge Nutritional Sciences plc is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Adam McCarter | Cavendish |
| Ian Berry | Cavendish Historical (Cenkos Securities) |
| John Savin | Edison Investment Research |